Janssen COVID-19 Vaccine
E49854
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
All labels observed (4)
| Label | Occurrences |
|---|---|
| Janssen COVID-19 Vaccine canonical | 5 |
| Janssen single-dose COVID-19 vaccine | 1 |
| Johnson & Johnson COVID-19 Vaccine | 1 |
| Johnson & Johnson COVID-19 vaccine | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T391443 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Janssen COVID-19 Vaccine Context triple: [Johnson & Johnson, covid19VaccineBrand, Janssen COVID-19 Vaccine]
-
A.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
B.
Vaccine Education Center
The Vaccine Education Center is a program at the Children's Hospital of Philadelphia that provides evidence-based information to the public about vaccines, vaccine safety, and immunization practices.
-
C.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
D.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
E.
Roche
Roche is a major Swiss multinational healthcare company and one of the world’s leading pharmaceutical and diagnostics firms.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Janssen COVID-19 Vaccine Target entity description: The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
-
A.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
B.
Vaccine Education Center
The Vaccine Education Center is a program at the Children's Hospital of Philadelphia that provides evidence-based information to the public about vaccines, vaccine safety, and immunization practices.
-
C.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
D.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
E.
Roche
Roche is a major Swiss multinational healthcare company and one of the world’s leading pharmaceutical and diagnostics firms.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
COVID-19 vaccine
ⓘ
pharmaceutical product ⓘ viral vector vaccine ⓘ |
| administrationSchedule | single intramuscular injection of 0.5 mL ⓘ |
| administrationSite | deltoid muscle ⓘ |
| ageGroupIndication | adults 18 years and older ⓘ |
| alsoKnownAs |
Ad26.COV2.S
ⓘ
Janssen COVID-19 Vaccine ⓘ
surface form:
Johnson & Johnson COVID-19 Vaccine
|
| antigen | SARS-CoV-2 spike protein ⓘ |
| ATCCode | J07BX03 ⓘ |
| belongsToCompany | Johnson & Johnson ⓘ |
| brandOwner | Janssen Pharmaceuticals ⓘ |
| clinicalTrialPhase3 | ENSEMBLE trial ⓘ |
| commonAdverseReactions |
fatigue
ⓘ
headache ⓘ injection site pain ⓘ myalgia ⓘ nausea ⓘ |
| contraindication |
known severe allergy to a component of the vaccine
ⓘ
severe allergic reaction to a previous dose ⓘ |
| countryOfFirstAuthorization |
United States of America
ⓘ
surface form:
United States
|
| dateOfFirstAuthorization | 2021-02-27 ⓘ |
| developer |
Janssen Pharmaceuticals
ⓘ
Johnson & Johnson ⓘ |
| doesNotRequire | ultra-cold storage ⓘ |
| doseRegimen | single dose ⓘ |
| efficacyAgainstSevereCOVID19 | higher than efficacy against moderate disease ⓘ |
| efficacyAgainstSymptomaticCOVID19 | approximately 66 percent in global phase 3 trial ⓘ |
| indication | prevention of COVID-19 in humans ⓘ |
| manufacturer |
Janssen Pharmaceuticals
ⓘ
Johnson & Johnson ⓘ |
| pharmaceuticalForm | suspension for injection ⓘ |
| rareAdverseEvents |
Guillain–Barré syndrome
ⓘ
thrombosis with thrombocytopenia syndrome ⓘ |
| regulatoryAgency |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| regulatoryStatusChange | use restricted in some countries due to safety concerns ⓘ |
| regulatorySubmissionType | Emergency Use Authorization ⓘ |
| routeOfAdministration | intramuscular injection ⓘ |
| storageRequirement | refrigeration ⓘ |
| storageTemperature | 2–8 °C ⓘ |
| targetDisease |
COVID-19 vaccines
ⓘ
surface form:
COVID-19
|
| targetVirus |
COVID-19 vaccines
ⓘ
surface form:
SARS-CoV-2
|
| technologyPlatform | Ad26 vector platform ⓘ |
| trialSponsor | Janssen Pharmaceuticals ⓘ |
| usesViralVector | human adenovirus serotype 26 (Ad26) ⓘ |
| vaccineType | non-replicating viral vector vaccine ⓘ |
| worldHealthOrganizationEULDate | 2021-03-12 ⓘ |
| worldHealthOrganizationStatus | Emergency Use Listing granted ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Janssen COVID-19 Vaccine Description of subject: The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
Referenced by (8)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
Johnson & Johnson COVID-19 Vaccine
subject surface form:
human adenovirus serotype 26
subject surface form:
human adenovirus serotype 26
subject surface form:
human adenovirus serotype 26
this entity surface form:
Johnson & Johnson COVID-19 vaccine
this entity surface form:
Janssen single-dose COVID-19 vaccine